Insider Buying: Ikena Oncology, Inc. (NASDAQ:IMA) Director Buys 267,556 Shares of Stock

Key Points

• Otello Stampacchia, a director at Ikena Oncology, acquired 267,556 shares at an average price of $29.90, increasing their total holdings by 142.75% to 454,982 shares.
• Ikena Oncology's stock traded at $15.29, with a market cap of $61.47 million and a price-to-earnings ratio of -1.99.
• Analysts have reduced the price target for Ikena Oncology from $25.00 to $23.00, maintaining a "neutral" rating on the stock.

Ikena Oncology, Inc. (NASDAQ:IMA - Get Free Report) Director Otello Stampacchia bought 267,556 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was purchased at an average price of $29.90 per share, for a total transaction of $7,999,924.40. Following the completion of the acquisition, the director owned 454,982 shares in the company, valued at $13,603,961.80. This represents a 142.75% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Ikena Oncology Trading Down 3.5%

Ikena Oncology stock traded down $0.62 on Friday, hitting $17.28. 11,207 shares of the stock traded hands, compared to its average volume of 45,097. The firm has a market cap of $69.47 million, a P/E ratio of -2.25 and a beta of 0.51. The business's fifty day simple moving average is $15.97 and its 200 day simple moving average is $15.79. Ikena Oncology, Inc. has a 1 year low of $11.65 and a 1 year high of $23.28.

Ikena Oncology (NASDAQ:IMA - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.08. As a group, analysts predict that Ikena Oncology, Inc. will post -0.91 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Wedbush dropped their price objective on Ikena Oncology from $25.00 to $23.00 and set a "neutral" rating for the company in a research note on Friday, July 25th.

Hedge Funds Weigh In On Ikena Oncology

Several large investors have recently modified their holdings of the stock. Squarepoint Ops LLC bought a new stake in Ikena Oncology in the 4th quarter worth about $72,000. BNP Paribas Financial Markets bought a new stake in shares of Ikena Oncology during the 4th quarter valued at about $72,000. XTX Topco Ltd grew its stake in shares of Ikena Oncology by 350.6% during the 1st quarter. XTX Topco Ltd now owns 56,452 shares of the company's stock valued at $72,000 after purchasing an additional 43,924 shares during the period. Northern Trust Corp grew its stake in shares of Ikena Oncology by 19.7% during the 4th quarter. Northern Trust Corp now owns 57,565 shares of the company's stock valued at $94,000 after purchasing an additional 9,456 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of Ikena Oncology by 62.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company's stock valued at $98,000 after purchasing an additional 29,369 shares during the period. Hedge funds and other institutional investors own 75.00% of the company's stock.

Ikena Oncology Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.